M
Mersana Therapeutics
MRSN
1.80000
USD
-0.205
(-10.22%)
مفتوح الان
حجم التداول
9,879
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
251,483,855
الأخبار
العنوان: Mersana Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.